(Press-News.org)
An investigational drug, encaleret, restored calcium levels in people with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder marked by an imbalance of calcium in the blood and urine, as well as abnormally low levels of parathyroid hormone, which regulates blood calcium levels. Led by clinician-scientists from the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health’s Clinical Center, results from the clinical trial are published in the New England Journal of Medicine.
In the mid-phase clinical trial, 13 participants with ADH1 received oral doses of the investigational drug for about 24 weeks. By the end of the trial, the treatment restored every participant’s blood calcium level to normal, and urine calcium approached normal levels. Levels of parathyroid hormone also normalized.
“It was amazing to see that every participant responded to the treatment. In literally minutes after taking the medication orally, the levels of parathyroid hormone increased dramatically,” said senior author and NIDCR endocrinologist Michael Collins, M.D.
Our bodies need calcium for proper functioning of many organs and tissues, including the bones, teeth, heart, muscles, and nerves. However, in people with ADH1, calcium levels in the blood are unusually low, leading to symptoms that can range from tingling limbs, muscle cramps, and brain fog to life-threatening seizures. Between 1.4 and 3.9 in 100,000 people in the U.S. are affected by the disease. While current therapies can help manage symptoms, there are no approved treatments that address the root cause of the condition.
“Conventional therapy is to raise the blood calcium level with calcium supplements and activated vitamin D,” said principal investigator and NIDCR pediatric endocrinologist Rachel Gafni, M.D. “However, too much of an increase could cause kidney stones or damage kidney tissues, leading to kidney failure in worst-case scenarios. The patients need better treatments, so we’re not constantly walking on a tightrope.”
Encaleret is thought to exert its effects by acting on faulty calcium-sensing receptors that are peppered throughout the kidneys and pea-sized organs in the neck called parathyroid glands. In healthy people, these receptors act like thermostats to monitor and control calcium levels. However, in patients with ADH1, the receptors are too sensitive and falsely interpret normal blood calcium levels as high. As a result, the parathyroid glands do not make enough parathyroid hormone and the kidneys flush too much calcium out of the body. This leads to low calcium levels in the blood and high levels in the urine.
“This clinical trial, which was made possible by a public-private partnership, really demonstrates the value of collaboration and the institute’s commitment and success in translating research into health,” said NIDCR Director Rena D’Souza, D.D.S., Ph.D.
Encaleret appeared to be safe and caused no serious side effects. However, because parathyroid hormone raises blood calcium levels in part by drawing calcium from the bones, the researchers noted a need to assess the treatment’s long-term effects on the skeleton. The researchers also speculate encaleret may have broader implications. An ongoing clinical trial led by Dr. Collins and NIDCR staff clinician Iris Hartley, M.D., is testing whether the treatment can help correct calcium levels in people whose parathyroid glands have been damaged by surgery.
“Because ADH1 can be passed on to offspring, the participants are not just doing this for themselves; it’s for their children, grandchildren, and great-grandchildren,” said Dr. Gafni. “One day, hopefully, we’ll be writing prescriptions for an effective treatment thanks to them.”
This research was supported by a public-private partnership between the NIDCR Division of Intramural Research and BridgeBio Pharma Inc. affiliate Calcilytix Therapeutics, Inc., under a Cooperative Research and Development Agreement.
Reference: Gafni RI, Hartley IR, Roszko KL, Nemeth EF, Pozo KA, Lombardi E, Sridhar AV, Roberts MS, Fox JC, Collins MT. Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1. N Engl J Med. 2023 Sep 28;389(13):1245-1247. doi: 10.1056/NEJMc2302708. PMID: 37754292.
About the National Institute of Dental and Craniofacial Research: NIDCR is the nation’s leading funder of research on oral, dental, and craniofacial health.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.
END
Reston, VA—A novel therapeutic approach that combines human epidermal growth receptor factor 2 (HER2)-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor growth. Monitored by immuno-PET scans, this combination therapy has the potential to personalize treatment for cancer patients and spare them from harmful side effects. This research was published in the October issue of The Journal of Nuclear Medicine.
Antibody-drug conjugates (ADCs) have become an eminent cancer treatment because of their ability to precisely target tumors with potent efficacy. HER2-ADC ...
It can be a relief to scratch the occasional itch, but when itch gets out of control, it can become a serious health problem. How does the body know when to stop?
Scientists at UC San Francisco are getting close to an answer. In a breakthrough that could transform how doctors treat conditions from eczema to allergies, they have discovered a feedback loop centered on a single immune protein called IL-31 that both causes the urge to itch and dials back nearby inflammation.
The findings, published on October 13th in Science Immunology, lay the groundwork ...
Newly published research on indoor air quality from Colorado State University shows wildfire smoke may linger in homes long after the initial blaze has been put out or winds have shifted.
The findings, published in Science Advances, show that wildfire smoke can attach to home surfaces like carpet, drapes or counters – extending the exposure for those inside and potentially causing health problems even after an initial cleaning activity by air purifiers. However, Professor Delphine Farmer said the research also shows that simple surface cleaning – like ...
CAMBRIDGE, MA -- The genome of the SARS-CoV-2 virus encodes 29 proteins, one of which is an ion channel called E. This channel, which transports protons and calcium ions, induces infected cells to launch an inflammatory response that damages tissues and contributes to the symptoms of Covid-19.
MIT chemists have now discovered the structure of the “open” state of this channel, which allows ions to flow through. This structure, combined with the “closed” state structure that was reported by the same lab in 2020, could help scientists ...
LEXINGTON, Ky. (Oct. 11, 2023) — On Tuesday, Oct. 10, a ribbon-cutting ceremony signified the official opening of Kentucky Children’s Richmond Road, the new home of four pediatric specialty clinics. This facility will offer a continuum of care to infants, children and adolescents with complex medical and behavioral needs.
“The mission of Kentucky Children’s Hospital has always been to provide the most advanced, comprehensive care to our patients and their families without them having to travel far from home,” said Scottie B. Day, M.D., physician-in-chief ...
The second SELINA thematic workshop took place from 2-5 October 2023 in Madrid, Spain, hosted by SELINA’s partner Rey Juan Carlos University. This hybrid event with the theme "Advancing solutions" (for mapping, assessment and accounting of ecosystems and their services) brought together over 100 participants (15 of them online) from all 27 EU member states, Israel, Norway, the UK and Switzerland. Apart from the SELINA partners, the event was also attended by the SELINA Advisory Board members ...
LEXINGTON, Ky. (Oct. 11, 2023) — The University of Kentucky has been selected as the nationwide coordination center for a National Institutes of Health (NIH) initiative. Danelle Stevens-Watkins, Ph.D., will lead the National Institute on Drug Abuse (NIDA) Racial Equity Initiative as principal investigator. The project is supported by a $3.4 million, five-year NIDA grant.
The UK Racial Equity Initiative Coordinating Center will be a national resource for researchers receiving funding to address health disparities ...
Three faculty members at the Johns Hopkins University School of Medicine have been elected to the National Academy of Medicine (NAM), an independent organization made up of leading professionals from multiple fields, such as public health, medicine, and natural, social and behavioral sciences. NAM serves alongside the National Academy of Sciences and the National Academy of Engineering as advisors to the national and international science communities.
The announcement of 100 new members was made October 9.
New members elected to NAM are chosen by current ...
A team of investigators from the UCLA Jonsson Comprehensive Cancer Center and the UCLA School of Dentistry received a five-year $4.6 million grant from the National Cancer Institute to develop and improve liquid biopsy technologies for the early detection of lung cancer — the leading cause of cancer death in both men and women in the U.S.
UCLA is one of five institutions in the nation that is part of the NCI Liquid Biopsy Consortium that is designed to find a better way to detect early signs of lung cancer in people with ...
NJIT has secured a $6 million grant from the National Science Foundation (NSF) to translate science and engineering discoveries into market-ready technologies that will improve quality of life in areas ranging from health care, to sustainable energy, to data privacy.
Awarded by the agency’s Directorate for Technology, Innovation, and Partnerships, the grant will accelerate the development of promising prototypes and enable market validation and other commercialization activities. It will also strengthen the university’s entrepreneurial culture ...
